Trochlear cell lymphoma is serious, mainly because of its aggressiveness and poor treatment outcome. Set-cell lymphoma is a new subtype of non-Hodgkin’s lymphoma REAL staging and WHO neostaging and accounts for 6% of non-Hodgkin’s lymphomas. It occurs most frequently in the elderly, with a median age of 60-65 years and a male-to-female ratio of 2:1. The predominant clinical manifestations are generalized superficial lymph node enlargement, often accompanied by B symptoms (30%), splenic invasion and bone marrow involvement. Extranodal lesions are more frequent, with the most common extranodal lesions being gastrointestinal (lymphomatous polyposis) and Weil’s rings. The first-line treatment regimens are HyperCVAD (vincristine, doxorubicin, cyclophosphamide and prednisone) and R-EPOCH regimen (rituximab, etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone). Due to the aggressive nature of the condylomatous lymphoma and its relatively poor response to treatment, the prognosis is poor, with a median survival time of 3 years after treatment, which is more severe.